Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 7881 - 7888 of 12086 results
U.S. Attorney Changes Mean Opportunities for Fraud Defendants
September 7, 2016| News
Energy and Environmental Legislative Updates for Fall 2016
September 6, 2016| Blog| Viewpoint
Back to Work from Travel Abroad? Check Your Form I-94!
September 6, 2016| Blog| Viewpoint
Summer Round-Up: Four States Bolster Data Breach Notification Laws and More Changes on the Way
September 2, 2016| Blog| Viewpoint
Final Rule Boosts Health-Care Penalties to Reflect Inflation
September 2, 2016| News
EB-5 Reauthorization Heading into Lame Duck Session of Congress
September 1, 2016| Blog| Viewpoint
FDA Announces Dates for Long-Awaited Public Hearing on Its Regulation of Off-Label Communications
September 1, 2016| Blog| Viewpoint
ITC Declines to File Petition for Certiorari – CAFC Holding that ITC Does Not Have Jurisdiction over Digital Imports Stands
September 1, 2016| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|